2014 marks 15 years in business for BioResource International, Inc. (BRI), a global biotechnology company specializing in the research, development and manufacture of high-performance enzyme feed additives for animal nutrition. The company attributes its continued success to the growing demand for its market-leading protease enzyme (Versazyme®), the launch of a new enzyme feed additive (XylamaxTM) and expansion into new markets.

During this past year, BRI expanded its product portfolio with the launch of Xylamax, a high-performance xylanase enzyme scientifically proven to help poultry and swine growers safely and effectively produce more protein, and XylaQuick, a companion qualitative in-feed colorimetric kit for on-site testing. To support the launch of Xylamax and XylaQuick, the company extended its network of strategic partners in high growth markets, including South Asia and Latin America, where BRI has signed distribution agreements with Jubilant Life Sciences and ilender Corp., respectively.

BRI continues to strengthen its position as an industry leader in the research and development of innovative biotechnology solutions for animal nutrition. In 2014, the company was granted new patents for the use of its protease enzyme in sorghum diets for poultry, and for use in swine production. BRI also successfully completed international quality audits resulting in GMP and FAMI-QS certifications for its U.S. manufacturing facility.

“At BRI, I like to talk about our progress in terms of three P’s – People, Products and Processes. Our greatest value can be measured in terms of our people, and they have worked tirelessly this past year to meet the challenges of a high-growth environment,” said Giles Shih, CEO. “We continue to leverage our scientific expertise to develop high-performance enzyme feed additives and launch new products. In terms of processes, we established new business partnerships and completed two international quality certifications.”

BRI’s revenue continues to increase at a compounded annual growth rate in excess of 20%, and production levels will more than double in the four years from 2012-2015. As a result, the company has nearly doubled its staff of PhD-level scientists, and has added new director level positions in Research and Development and Finance.